109568
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
替雷利珠单抗诱导的天疱疮样扁平苔藓病例报告
Authors Xie X , Chen J, Luo Y, Zhou X, Ma S
Received 25 June 2025
Accepted for publication 28 August 2025
Published 21 October 2025 Volume 2025:18 Pages 2707—2711
DOI https://doi.org/10.2147/CCID.S549402
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Michela Starace
Xinyi Xie,1,2,* Jiaoquan Chen,1,2,* Yuwu Luo,1,2 Xin Zhou,1 Shaoyin Ma1,2
1Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, People’s Republic of China; 2Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xin Zhou, Department of Dermatology, Guangzhou Dermatology Hospital, 56 Hengfu Road Guangzhou, Guangdong, 510095, People’s Republic of China, Email rain0504@sina.com Shaoyin Ma, Department of Dermatology, Guangzhou Dermatology Hospital, 56 Hengfu Road Guangzhou, Guangdong, 510095, People’s Republic of China, Email msymsb315@163.com
Abstract: Lichen planus pemphigoides (LPP) is a rare autoimmune subepidermal bullous disorder characterized by lichenoid lesions resembling lichen planus (LP) and bullous pemphigoid(BP). LPP may be triggered by medications, malignancies, or viral infections. Herein, we present a 67-year-old male patient with brain-metastatic non-small cell lung cancer (NSCLC) who developed pruritic violaceous plaques, tense bullae, and verrucous hyperplasia on the trunk and extremities following tislelizumab therapy. Histopathological examination confirmed LPP. The condition significantly improved with methylprednisolone combined with dupilumab treatment, and there was no recurrence during a 10-month follow-up.
Keywords: lichen planus pemphigoides, dupilumab, PD-1 inhibitors, tislelizumab, immune-related cutaneous adverse event
1Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, Guangdong, People’s Republic of China; 2Guangzhou Medical University, Guangzhou, Guangdong, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xin Zhou, Department of Dermatology, Guangzhou Dermatology Hospital, 56 Hengfu Road Guangzhou, Guangdong, 510095, People’s Republic of China, Email rain0504@sina.com Shaoyin Ma, Department of Dermatology, Guangzhou Dermatology Hospital, 56 Hengfu Road Guangzhou, Guangdong, 510095, People’s Republic of China, Email msymsb315@163.com
Abstract: Lichen planus pemphigoides (LPP) is a rare autoimmune subepidermal bullous disorder characterized by lichenoid lesions resembling lichen planus (LP) and bullous pemphigoid(BP). LPP may be triggered by medications, malignancies, or viral infections. Herein, we present a 67-year-old male patient with brain-metastatic non-small cell lung cancer (NSCLC) who developed pruritic violaceous plaques, tense bullae, and verrucous hyperplasia on the trunk and extremities following tislelizumab therapy. Histopathological examination confirmed LPP. The condition significantly improved with methylprednisolone combined with dupilumab treatment, and there was no recurrence during a 10-month follow-up.
Keywords: lichen planus pemphigoides, dupilumab, PD-1 inhibitors, tislelizumab, immune-related cutaneous adverse event